Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Inhaled S-nitrosoglutathione for Bronchopulmonary Dysplasia
NCT04619602Phase 1Withdrawn
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of S-nitrosoglutathione in bronchopulmonary dysplasia (BPD), sponsored by University Hospitals Cleveland Medical Center. Primary endpoint: Treatment Emergent Adverse Events at 7 days. Planned start Aug 2025; status: withdrawn.
02
Drugs
S-nitrosoglutathione
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT04619602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619602.